Great Novel Therapeutics Biotech & Medicals (TPEX:7427)
Taiwan · Delayed Price · Currency is TWD 73.50
+0.10 (0.14%)
Sep 8, 2026, 1:48 PM CST
TPEX:7427 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6.21 | 1.21 | 1.69 | 4.85 | 0.54 | 0.63 | |
Revenue Growth | 248.57% | -28.49% | -65.26% | 798.15% | -14.29% | - |
Cost of Revenue | 5.05 | 2.39 | 0.67 | 0.04 | 0.08 | 0.35 |
Gross Profit | 1.16 | -1.18 | 1.02 | 4.81 | 0.46 | 0.28 |
Selling, General & Admin | 38.46 | 26.47 | 28.57 | 17.5 | 19.37 | 17.7 |
Research & Development | 79.8 | 71.89 | 85.09 | 53.13 | 49.89 | 19.11 |
Operating Expenses | 118.25 | 98.36 | 113.66 | 70.63 | 69.26 | 36.8 |
Operating Income | -117.09 | -99.54 | -112.65 | -65.82 | -68.79 | -36.52 |
Interest Expense | -0.08 | -0.1 | -0.13 | -0.09 | - | - |
Interest & Investment Income | 7.76 | 8.02 | 7.79 | 5.33 | 0.94 | 0.52 |
Currency Exchange Gain (Loss) | -0.11 | -0.16 | 0.06 | -0.54 | 0.33 | 0.13 |
Other Non Operating Income (Expenses) | -1.21 | 0.01 | 0 | 0 | 0.39 | 0.02 |
EBT Excluding Unusual Items | -110.73 | -91.78 | -104.92 | -61.12 | -67.13 | -35.86 |
Gain (Loss) on Sale of Assets | - | - | - | 0.12 | - | - |
Asset Writedown | -0.93 | -0.93 | - | - | - | - |
Other Unusual Items | - | -4.76 | - | - | - | - |
Pretax Income | -111.67 | -97.47 | -104.92 | -61 | -67.13 | -35.86 |
Net Income | -111.67 | -97.47 | -104.92 | -61 | -67.13 | -35.86 |
Net Income to Common | -111.67 | -97.47 | -104.92 | -61 | -67.13 | -35.86 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 44 | 43 | 41 | 36 | 24 | 21 |
Shares Outstanding (Diluted) | 44 | 43 | 41 | 36 | 24 | 21 |
Shares Change | 2.13% | 4.46% | 13.60% | 50.23% | 14.54% | 33.09% |
EPS (Basic) | -2.52 | -2.26 | -2.55 | -1.68 | -2.78 | -1.70 |
EPS (Diluted) | -2.52 | -2.26 | -2.55 | -1.68 | -2.78 | -1.70 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -88.07 | -87.84 | -78.96 | -57.92 | -77.21 | -33.96 |
Free Cash Flow Per Share | -1.99 | -2.04 | -1.92 | -1.60 | -3.20 | -1.61 |
Gross Margin | 18.72% | -98.26% | 60.24% | 99.11% | 85.93% | 44.92% |
Operating Margin | -1886.11% | -8260.91% | -6685.28% | -1357.11% | -12739.07% | -5796.98% |
Profit Margin | -1798.73% | -8089.05% | -6226.94% | -1257.67% | -12431.85% | -5691.59% |
Free Cash Flow Margin | -1418.65% | -7289.46% | -4685.82% | -1194.21% | -14298.70% | -5389.68% |
EBITDA | -113.22 | -94.81 | -108.62 | -63.22 | -67.03 | -35.08 |
D&A For EBITDA | 3.87 | 4.74 | 4.03 | 2.6 | 1.76 | 1.44 |
EBIT | -117.09 | -99.54 | -112.65 | -65.82 | -68.79 | -36.52 |
Advertising Expenses | - | 0.25 | - | - | - | - |